Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

Original reporting
Published Nov 18, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Passage Bio Received Notice of Noncompliance — source image
Decision brief

The 30-second read

$PASGBearishMed
01

Why it matters

The filing reports a noncompliance notice tied to equity shortfall, creating a compliance and potential delisting overhang. The company’s stated expectation is that its pending merger with Remix Therapeutics will restore compliance after closing, and the shares are expected to trade under a new symbol post-close.

02

Market read

This is a company-specific exchange compliance risk update that can drive near-term volatility and position sizing decisions until merger closing reduces delisting concerns.

03

What to watch

Traders should monitor merger closing timeline, any Nasdaq cure period details not included here, and whether the company’s equity figure implies broader balance-sheet stress beyond the listing rule.

Relevance 7/10Novelty 7/10Timing: after-hours/next-session reaction to the 8-K noncompliance notice

Background

Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders' equity, with alternative requirements available if the primary threshold is not met.

Company-level read

Ticker impact

$PASGBearishMedium confidence
Context

Passage Bio disclosed a Nasdaq Listing Rule 5550(b)(1) noncompliance notice after reporting only $50,000 stockholders' equity versus the $2.5M requirement.

Expected impact

Likely downward pressure or volatility as traders price delisting/compliance risk until merger closing clarity improves.

Evidence & confidence

The notice itself has no immediate trading effect, but it signals potential listing risk and can affect liquidity and sentiment. The merger-based compliance plan may cushion the impact, yet timing uncertainty remains.

Market effects

Biotech microcap listing-compliance headlines can modestly raise perceived delisting risk across similar Nasdaq-listed development-stage issuers.

Primarily US microcap sentiment, with limited spillover beyond Nasdaq biotech peers.

Low, as the event is exchange-specific and not tied to global macro or cross-border fundamentals.

Counterpoint

Because the notice states it has no immediate effect and the company expects merger closing to restore compliance, the market may treat this as procedural rather than existential.

Key entities

  • Passage Bio, Inc.

    Nasdaq-listed biotech that received a noncompliance notice for insufficient stockholders' equity under Rule 5550(b)(1).

  • Remix Therapeutics

    Counterparty in Passage Bio’s pending merger expected to restore Nasdaq compliance after closing.

Related articles

$PNFPMed

Pinnacle Bank, a wholly-owned subsidiary of Pinnacle Financial Partners, Inc., issued $600 million aggregate principal amount of its 7.200% Fixed-to-Floating…

Pinnacle Financial Partners, Inc. (PNFP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 18, 2026, Pinnacle Bank (the “Bank”), a wholly-owned subsidiary of Pinnacle Financial Partners, Inc. (the “Company”), issued $600 million aggregate principal amount of its 7.200% Fixed-to-Floating Rate Subordinated Bank Notes due 2038 (the “Sub

$NXPIMed

NXP B.V., NXP Funding LLC, NXP USA, Inc. and NXP Semiconductors N.V. executed and delivered an underwriting agreement, by and among the Issuers, the Company…

NXP Semiconductors N.V. (NXPI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 17, 2026, NXP B.V., NXP Funding LLC, NXP USA, Inc. (the “ Issuers ”) and NXP Semiconductors N.V. (the “ Company ”) executed and delivered an underwriting agreement (the “ Underwriting Agreement ”), by and among the Issuers, the Company and BNP

$DANMed

Dana Incorporated, a Delaware corporation, announced that it had commenced offers to purchase for cash any and all of the Company’s outstanding (i) 4.250%…

DANA Inc (DAN) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 6, 2026, Dana Incorporated, a Delaware corporation (the “Company”), announced that it had commenced offers to purchase for cash (collectively, the “Tender Offers”) any and all of the Company’s outstanding (i) 4.250% Senior Notes due 2030 (the